Drug Trial Radar · NCT06551506
The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both Products
Last checked: Nov 20, 2026Latest source record: May 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
181
Actual
Start
Sep 19, 2024
Primary completion
May 5, 2026
Study completion May 5, 2026
Sponsor
- Sponsor type
- NIH
- First posted
- Aug 13, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Respiratory Syncytial Virus (RSV) is the leading cause of lower respiratory tract infections (LRTIs) in infants and young children. It is also a leading cause of mortality in children \<5 years of age worldwide. Until recently, no Food and Drug Administration (FDA)-approved vaccines were available to prevent RSV infection. The only prophylactic product for RSV prevention recommended for infants was the monoclonal antibody palivizumab, but administration was limited to those with extreme prematurity, chronic lung disease, or hemodynamically significant congenital heart disease. However, in 2023, the FDA approved two products designed to prevent RSV lower respiratory tract disease (LRTD) in all infants: an active RSV vaccine based on the prefusion F protein (RSVpreF, ABRYSVO, Pfizer) administered during pregnancy, and a passive, long-acting monoclonal antibody (nirsevimab-alip \[henceforth referred to as nirsevimab\], BEYFORTUS, AstraZeneca) administered to infants at birth or at the start of their first RSV season. Both products were evaluated in Phase 3 pivotal clinical trials and have high efficacy in preventing LRTD caused by RSV in infants. Although there is no established correlate of protection against RSV, antibodies have been associated with protection across multiple studies. The clinical development plan for the products did not include comprehensive evaluations of the magnitude and durability of the immune response, nor were the two products tested in a single trial. This study is a prospective, randomized, open-label Phase 4 study with the primary objective of evaluating the magnitude and durability of RSV-specific neutralizing antibodies in infants through 12 months of life following either maternal RSV vaccination, infant nirsevimab administration, or both products combined.
Conditions
- Respiratory Syncytial Virus Infection
Interventions
AbrysvoBiological
A maternal RSV vaccine based on the prefusion F protein administered during pregnancy
BeyfortusBiological
A passive, long-acting monoclonal antibody to Respiratory syncytial virus (RSV) administered to infants
Primary outcomes
What the sponsor says the trial is designed to measure.
- Geometric mean titer (GMT) of serum RSV A and B neutralizing antibodies in infantsTime frame: Through Day 366
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Emory University School of Medicine
Atlanta, Georgia
University of Maryland, School of Medicine, Center for Vaccine Development and Global Health
Baltimore, Maryland
New York University School of Medicine - Langone Medical Center - Vaccine Center
New York, New York
University of Rochester Medical Center - Vaccine Research Unit
Rochester, New York
Cincinnati Children's Hospital Medical Center Vaccine Research Center
Cincinnati, Ohio
University of Pittsburgh - Medicine - Infectious Diseases
Pittsburgh, Pennsylvania
Vanderbilt University Medical Center
Nashville, Tennessee
Baylor College of Medicine
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.